Ultragenyx Pharmaceutical Inc.
Cash Flow Statement
| Line Item | FY2017 | FY2016 | FY2015 | FY2014 | FY2013 | FY2012 |
|---|---|---|---|---|---|---|
| Operating Activities | ||||||
| Net Income | $-302.1M | $-245.9M | $-145.6M | $-59.8M | $-35.1M | $-16.3M |
| Depreciation & Amortization | $5.8M | $3.4M | $1.4M | $684.0K | $444.0K | $313.0K |
| Depreciation | — | — | — | — | — | — |
| Amortization | — | — | — | — | — | — |
| Stock-Based Compensation | $68.0M | $48.3M | $24.9M | $5.4M | $657.0K | $891.0K |
| Net Cash from Operating Activities | $-253.8M | $-161.0M | $-106.0M | $-44.6M | $-31.2M | $-12.5M |
| Investing Activities | ||||||
| Capital Expenditures | $2.8M | $10.2M | $5.0M | $2.1M | $407.0K | $1.1M |
| Business Acquisitions | $142.8M | — | — | — | — | — |
| Net Cash from Investing Activities | $55.5M | $91.1M | — | — | — | — |
| Financing Activities | ||||||
| Dividends Paid | — | — | — | — | — | — |
| Stock Repurchases | — | — | — | — | — | — |
| Net Cash from Financing Activities | $136.3M | $138.7M | — | — | — | — |
| Net Change in Cash | $-60.6M | $67.6M | $69.2M | $16.9M | $-78.8M | $75.5M |
| Free Cash Flow | $-256.6M | $-171.2M | $-110.9M | $-46.8M | $-31.6M | $-13.6M |